^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Reqorsa (quaratusugene ozeplasmid) (Apoptosis stimulant, Immunomodulator, Gene transference, TUSC2 gene stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
76 - TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice
Published date:
03/10/2021
Excerpt:
Oncogenic KRAS-LKB1 (KL)-mutant NSCLC...The chemo-immune (carbo+pembro) combination significantly reduced tumor burden over chemo or ICB alone. When TUSC2 was added to the chemo+immune combination, metastases regression was significantly greater than either TUSC2...Similarly, TUSC2 also showed enhanced efficacy with carbo+aPD1 in highly metastatic KRASmt CMT167 in syngeneic mice.
Secondary therapy:
carboplatin